{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7"}]}],"title":"Complete"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5"}]}],"title":"Partial"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"}]}],"title":"Progression"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Stable"}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"}],"units":"Participants"}],"description":"Objective Tumor Response reported on participants at 1 year (complete, partial, progression, or stable response).","groups":[{"description":"Erlotinib\n\nerlotinib hydrochloride\n\npemetrexed disodium\n\nquality-of-life assessment\n\nintensity-modulated radiation therapy","id":"OG000","title":"Erlotinib"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Data corresponds to Phase II patients.","reportingStatus":"POSTED","timeFrame":"1 year","title":"Objective Tumor Response","type":"SECONDARY","unitOfMeasure":"Participants"}